Medical Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

Reason(s) for the decline in use of H₂ blockers obtained by prescription.
1. Recognition of the importance of Helicobacter Pylorii in the etiology of peptic ulcer disease (treated by antibiotic administration)
2. Introduction of the class of proton pump inhibitors, e.g. omeprazole.
3. Both
4. Neither
H₂ antagonist(s) and current, clinical use:
1. Famotidine (Pepcid)
2. Nizatidine (Axid)
3. Ranitidine (Zantac)
4. Cimetidine (Tagamet)
5. A & B
6. B & C
7. A, B & C
8. A, B, C & D (all of the drugs are in current clinical use)
Characteristic(s) of most of the currently used H₂ antagonists (blockers):
1. Rapidly absorbed from the G.I. tract
2. Undergo notable first-past liver metabolism decreasing bioavailability to about 50%.
3. Both
4. Neither
Exhibiting limited first-pass metabolism:
1. Cimetidine
2. Ranitidine
3. Nizatidine
4. Famotidine
Exhibits the highest relative potency (compared to cimetidine):
1. Nizatidine
2. Famotidine
3. Ranitidine
Clearance mechanism(s) associated with elimination of H₂ blockers:
1. Glomerular filtration
2. Hepatic metabolism
3. Both
4. Neither
H₂ receptor antagonists decrease 24-hour gastric acid secretion by about 70%.
1. True
2. False
H₂ receptor blockers are appropriate for management of bleeding ulcers.
1. True
2. False
Which one(s) of the following H2 receptor antagonists is/are available for IV and intramuscular administration for potential use in critically sick patients?
1. Famotidine
2. Ranitidine
3. Cimetidine
4. A & C
5. A, B & C
Concerning absorption of H₂ receptor blockers:
1. Generally rapidly absorbed after oral dosing.
2. Maximal serum concentration reached within 1-3 hours.
3. Both
4. Neither